Navigation Links
Leading global Big Pharma companies of 2005

I always look forward to writing this particular article with great anticipation! Why, you say? It is part of an annual ritual that I have followed with eagerness as I grew up in the pharmaceutical industry, initiating in my 10 years at Pfizer (way before Pfizer was the juggernaut it is today). At Pfizer, we were all anxious to see the annual company ranking results ......

Full article >>> an old friend and colleague who was retiring from Pfizer the week that I was there, after 31 years with the company. In fact, he and I started at Pfizer the same year (wow, I was really feeling old).

As I toured Pfizer Brazil's offices, we were reminiscing of the old days when Pfizer's offices in most Latin American countries were usually located 45 minutes to an hour from city centers a......

Full article >>> >N/ARoche* (Swiss + Chugai)$15.7N/A99Wyeth (U.S.)$15.3+10%108Bristol-Myers Squibb$15.3<1%>1111Eli Lilly (U.S.)$14.7+12%1210Abbott Labs (U.S.)$14.0+16%
Full article >>> les from acquisition of Japanese company Chugai but does not include sales from majority-owned position in Genentech
** merger of Yamanouchi and Fujisawa to become Astellas
*** does not include recently-announced acquisition of Schering AG
**** merger in September, 2005 of Daiichi and Sankyo

By the way, as a manner of comparison, let's take a look at the rankings of the pharm......

Full article >>> re within the top 30 companies, Amgen and Genentech, with Amgen close to breaking into the top 10 companies although its growth is slowing down; Genentech continues to move up in the ranks and actually finished the year with a market cap higher than Amgen's - approaching $100 billion
  • The Japanese companies continue to globalize due to the weakness of their own home market and inc......

    Full article >>> 6Novartis$4.518.0%7Roche (includes Chugai)$4.226.8%8Merck$3.817.3%9Eli Lilly$3.020.4%10Amgen$2.319.2%11Schering-Plough$1.925.0%
    Full article >>> >Abbott Labs at about 13% of sales is on the low side while Eli Lilly is aggressively investing (20% of sales); Baxter, at about 17% of sales, is just slightly above the average for the industry.

    Note that, on average, 50% of a Big Pharma's R&D budget is being spent on the development of in-licensed drugs (from smaller companies), with some companies spend......

    Full article >>> altimore, Chicago, Cleveland, and Denver. Rosen is also a founder and board member of the Illinois Biotechnology Industry Organization. He can be reached at rosenmichaels@aol.com

  • The opinions expressed herein or statements made in the above column are solely those of the author and do not necessarily reflect th......

    Full article >>>
    '"/>

    Source:wistechnology.com By Michael Rosen 05/09/06


    Related biology technology :

    1. Leading cancer institute to install three TomoTherapy systems
    2. The state of global biotech: An Ernst & Young perspective
    3. Doyle announces new energy, global warming policies
    4. Lucigen Corp. enters global licensing agreement
    5. Work-life imbalance - A global problem getting worse
    6. Learning to swim in the global talent pool
    7. Federal and global guidelines on stem cell research offer a level playing field
    8. Wisconsin plant is part of NCRs global RFID initiative
    9. Whither Wisconsin manufacturing in the new global economy?
    10. In the wake of Katrina, more questions than answers about global climate change
    11. Is America prepared to win the global skills race?
    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
    (Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
    (Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
    (Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
    Breaking Biology Technology:
    (Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
    (Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
    (Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
    Breaking Biology News(10 mins):